Nanotherapies for the treatment of ocular diseases
[Display omitted] •Nanosystems can interact with the ocular mucosa upon topical administration.•Improved interactions translate into improved therapeutic efficacies.•The potential of nanotechnology has been demonstrated for prevalent ocular diseases. The topical route is the most frequent and prefer...
Gespeichert in:
| Veröffentlicht in: | European journal of pharmaceutics and biopharmaceutics 2015-09, Vol.95 (Pt B), p.279-293 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 293 |
|---|---|
| container_issue | Pt B |
| container_start_page | 279 |
| container_title | European journal of pharmaceutics and biopharmaceutics |
| container_volume | 95 |
| creator | Reimondez-Troitiño, S. Csaba, N. Alonso, M.J. de la Fuente, M. |
| description | [Display omitted]
•Nanosystems can interact with the ocular mucosa upon topical administration.•Improved interactions translate into improved therapeutic efficacies.•The potential of nanotechnology has been demonstrated for prevalent ocular diseases.
The topical route is the most frequent and preferred way to deliver drugs to the eye. Unfortunately, the very low ocular drug bioavailability (less than 5%) associated with this modality of administration, makes the efficient treatment of several ocular diseases a significant challenge. In the last decades, it has been shown that specific nanocarriers can interact with the ocular mucosa, thereby increasing the retention time of the associated drug onto the eye, as well as its permeability across the corneal and conjunctival epithelium. In this review, we comparatively analyze the mechanism of action and specific potential of the most studied nano-drug delivery carriers. In addition, we present the success achieved until now using a number of nanotherapies for the treatment of the most prevalent ocular pathologies, such as infections, inflammation, dry eye, glaucoma, and retinopathies. |
| doi_str_mv | 10.1016/j.ejpb.2015.02.019 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1722186985</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0939641115001010</els_id><sourcerecordid>1722186985</sourcerecordid><originalsourceid>FETCH-LOGICAL-c492t-30b5e3198395c3c3eb50c36bb77ffdc8260932b94b2c965891530e3393d588143</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMo7rr6BzxIj15a89G0CXiRxS9Y9KLnkKRTTGmbmrSC_94uXT16Ggae92XmQeiS4IxgUtw0GTSDySgmPMM0w0QeoTURJUtZnpNjtMaSybTICVmhsxgbjHFecnGKVpSXlNOCrhF90b0fPyDowUFMah-SeUvGAHrsoB8TXyfeTq0OSeUi6AjxHJ3Uuo1wcZgb9P5w_7Z9Snevj8_bu11qc0nHlGHDgREpmOSWWQaGY8sKY8qyrisraDGfR43MDbWy4EISzjAwJlnFhSA526DrpXcI_nOCOKrORQttq3vwU1SkpJSIQgo-o3RBbfAxBqjVEFynw7ciWO1dqUbtXam9K4Wpml3NoatD_2Q6qP4iv3Jm4HYBYP7yy0FQ0TroLVQugB1V5d1__T9Tg3iP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1722186985</pqid></control><display><type>article</type><title>Nanotherapies for the treatment of ocular diseases</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Reimondez-Troitiño, S. ; Csaba, N. ; Alonso, M.J. ; de la Fuente, M.</creator><creatorcontrib>Reimondez-Troitiño, S. ; Csaba, N. ; Alonso, M.J. ; de la Fuente, M.</creatorcontrib><description>[Display omitted]
•Nanosystems can interact with the ocular mucosa upon topical administration.•Improved interactions translate into improved therapeutic efficacies.•The potential of nanotechnology has been demonstrated for prevalent ocular diseases.
The topical route is the most frequent and preferred way to deliver drugs to the eye. Unfortunately, the very low ocular drug bioavailability (less than 5%) associated with this modality of administration, makes the efficient treatment of several ocular diseases a significant challenge. In the last decades, it has been shown that specific nanocarriers can interact with the ocular mucosa, thereby increasing the retention time of the associated drug onto the eye, as well as its permeability across the corneal and conjunctival epithelium. In this review, we comparatively analyze the mechanism of action and specific potential of the most studied nano-drug delivery carriers. In addition, we present the success achieved until now using a number of nanotherapies for the treatment of the most prevalent ocular pathologies, such as infections, inflammation, dry eye, glaucoma, and retinopathies.</description><identifier>ISSN: 0939-6411</identifier><identifier>EISSN: 1873-3441</identifier><identifier>DOI: 10.1016/j.ejpb.2015.02.019</identifier><identifier>PMID: 25725262</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Administration, Ophthalmic ; Animals ; Biological Availability ; Conjunctiva - metabolism ; Cornea - metabolism ; Drug delivery ; Drug Delivery Systems ; Epithelium - metabolism ; Eye Diseases - drug therapy ; Gene delivery ; Humans ; Nanoparticles ; Nanotechnology ; Ocular ; Permeability ; Topical administration</subject><ispartof>European journal of pharmaceutics and biopharmaceutics, 2015-09, Vol.95 (Pt B), p.279-293</ispartof><rights>2015 Elsevier B.V.</rights><rights>Copyright © 2015 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c492t-30b5e3198395c3c3eb50c36bb77ffdc8260932b94b2c965891530e3393d588143</citedby><cites>FETCH-LOGICAL-c492t-30b5e3198395c3c3eb50c36bb77ffdc8260932b94b2c965891530e3393d588143</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejpb.2015.02.019$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25725262$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Reimondez-Troitiño, S.</creatorcontrib><creatorcontrib>Csaba, N.</creatorcontrib><creatorcontrib>Alonso, M.J.</creatorcontrib><creatorcontrib>de la Fuente, M.</creatorcontrib><title>Nanotherapies for the treatment of ocular diseases</title><title>European journal of pharmaceutics and biopharmaceutics</title><addtitle>Eur J Pharm Biopharm</addtitle><description>[Display omitted]
•Nanosystems can interact with the ocular mucosa upon topical administration.•Improved interactions translate into improved therapeutic efficacies.•The potential of nanotechnology has been demonstrated for prevalent ocular diseases.
The topical route is the most frequent and preferred way to deliver drugs to the eye. Unfortunately, the very low ocular drug bioavailability (less than 5%) associated with this modality of administration, makes the efficient treatment of several ocular diseases a significant challenge. In the last decades, it has been shown that specific nanocarriers can interact with the ocular mucosa, thereby increasing the retention time of the associated drug onto the eye, as well as its permeability across the corneal and conjunctival epithelium. In this review, we comparatively analyze the mechanism of action and specific potential of the most studied nano-drug delivery carriers. In addition, we present the success achieved until now using a number of nanotherapies for the treatment of the most prevalent ocular pathologies, such as infections, inflammation, dry eye, glaucoma, and retinopathies.</description><subject>Administration, Ophthalmic</subject><subject>Animals</subject><subject>Biological Availability</subject><subject>Conjunctiva - metabolism</subject><subject>Cornea - metabolism</subject><subject>Drug delivery</subject><subject>Drug Delivery Systems</subject><subject>Epithelium - metabolism</subject><subject>Eye Diseases - drug therapy</subject><subject>Gene delivery</subject><subject>Humans</subject><subject>Nanoparticles</subject><subject>Nanotechnology</subject><subject>Ocular</subject><subject>Permeability</subject><subject>Topical administration</subject><issn>0939-6411</issn><issn>1873-3441</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LxDAQhoMo7rr6BzxIj15a89G0CXiRxS9Y9KLnkKRTTGmbmrSC_94uXT16Ggae92XmQeiS4IxgUtw0GTSDySgmPMM0w0QeoTURJUtZnpNjtMaSybTICVmhsxgbjHFecnGKVpSXlNOCrhF90b0fPyDowUFMah-SeUvGAHrsoB8TXyfeTq0OSeUi6AjxHJ3Uuo1wcZgb9P5w_7Z9Snevj8_bu11qc0nHlGHDgREpmOSWWQaGY8sKY8qyrisraDGfR43MDbWy4EISzjAwJlnFhSA526DrpXcI_nOCOKrORQttq3vwU1SkpJSIQgo-o3RBbfAxBqjVEFynw7ciWO1dqUbtXam9K4Wpml3NoatD_2Q6qP4iv3Jm4HYBYP7yy0FQ0TroLVQugB1V5d1__T9Tg3iP</recordid><startdate>20150901</startdate><enddate>20150901</enddate><creator>Reimondez-Troitiño, S.</creator><creator>Csaba, N.</creator><creator>Alonso, M.J.</creator><creator>de la Fuente, M.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150901</creationdate><title>Nanotherapies for the treatment of ocular diseases</title><author>Reimondez-Troitiño, S. ; Csaba, N. ; Alonso, M.J. ; de la Fuente, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c492t-30b5e3198395c3c3eb50c36bb77ffdc8260932b94b2c965891530e3393d588143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Administration, Ophthalmic</topic><topic>Animals</topic><topic>Biological Availability</topic><topic>Conjunctiva - metabolism</topic><topic>Cornea - metabolism</topic><topic>Drug delivery</topic><topic>Drug Delivery Systems</topic><topic>Epithelium - metabolism</topic><topic>Eye Diseases - drug therapy</topic><topic>Gene delivery</topic><topic>Humans</topic><topic>Nanoparticles</topic><topic>Nanotechnology</topic><topic>Ocular</topic><topic>Permeability</topic><topic>Topical administration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reimondez-Troitiño, S.</creatorcontrib><creatorcontrib>Csaba, N.</creatorcontrib><creatorcontrib>Alonso, M.J.</creatorcontrib><creatorcontrib>de la Fuente, M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmaceutics and biopharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Reimondez-Troitiño, S.</au><au>Csaba, N.</au><au>Alonso, M.J.</au><au>de la Fuente, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nanotherapies for the treatment of ocular diseases</atitle><jtitle>European journal of pharmaceutics and biopharmaceutics</jtitle><addtitle>Eur J Pharm Biopharm</addtitle><date>2015-09-01</date><risdate>2015</risdate><volume>95</volume><issue>Pt B</issue><spage>279</spage><epage>293</epage><pages>279-293</pages><issn>0939-6411</issn><eissn>1873-3441</eissn><abstract>[Display omitted]
•Nanosystems can interact with the ocular mucosa upon topical administration.•Improved interactions translate into improved therapeutic efficacies.•The potential of nanotechnology has been demonstrated for prevalent ocular diseases.
The topical route is the most frequent and preferred way to deliver drugs to the eye. Unfortunately, the very low ocular drug bioavailability (less than 5%) associated with this modality of administration, makes the efficient treatment of several ocular diseases a significant challenge. In the last decades, it has been shown that specific nanocarriers can interact with the ocular mucosa, thereby increasing the retention time of the associated drug onto the eye, as well as its permeability across the corneal and conjunctival epithelium. In this review, we comparatively analyze the mechanism of action and specific potential of the most studied nano-drug delivery carriers. In addition, we present the success achieved until now using a number of nanotherapies for the treatment of the most prevalent ocular pathologies, such as infections, inflammation, dry eye, glaucoma, and retinopathies.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>25725262</pmid><doi>10.1016/j.ejpb.2015.02.019</doi><tpages>15</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-6411 |
| ispartof | European journal of pharmaceutics and biopharmaceutics, 2015-09, Vol.95 (Pt B), p.279-293 |
| issn | 0939-6411 1873-3441 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1722186985 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Administration, Ophthalmic Animals Biological Availability Conjunctiva - metabolism Cornea - metabolism Drug delivery Drug Delivery Systems Epithelium - metabolism Eye Diseases - drug therapy Gene delivery Humans Nanoparticles Nanotechnology Ocular Permeability Topical administration |
| title | Nanotherapies for the treatment of ocular diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T11%3A53%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nanotherapies%20for%20the%20treatment%20of%20ocular%20diseases&rft.jtitle=European%20journal%20of%20pharmaceutics%20and%20biopharmaceutics&rft.au=Reimondez-Troiti%C3%B1o,%20S.&rft.date=2015-09-01&rft.volume=95&rft.issue=Pt%20B&rft.spage=279&rft.epage=293&rft.pages=279-293&rft.issn=0939-6411&rft.eissn=1873-3441&rft_id=info:doi/10.1016/j.ejpb.2015.02.019&rft_dat=%3Cproquest_cross%3E1722186985%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1722186985&rft_id=info:pmid/25725262&rft_els_id=S0939641115001010&rfr_iscdi=true |